Soligenix Inc. Advances in Oral Mucositis Treatment with SGX942

Soligenix Inc. (NASDAQ: SNGX) is at the forefront of addressing severe oral mucositis (SOM), a painful and debilitating side effect of cancer therapy, with its innovative treatment SGX942. This condition, which currently lacks FDA-approved treatments, significantly impacts the quality of life for patients, often leading to hospitalization, the need for opioid pain management, and feeding tube placement. SGX942 aims to mitigate these effects by reducing tissue inflammation, promoting healing, and supporting the immune response.

The company is currently analyzing combined phase 2 and 3 datasets to inform the design of a subsequent phase 3 study. Preliminary phase 3 data has already demonstrated notable improvements in the duration and severity of mucositis among head and neck cancer patients. Oral mucositis arises when chemotherapy or radiation damages the mouth's mucous membranes, resulting in painful ulcers, inflammation, and compromised oral function, a common issue for those undergoing head and neck cancer treatments.

For further details on Soligenix's developments, interested parties can visit the company's newsroom at https://ibn.fm/SNGX.